In one study, serial sampling of patient sera revealed that 9 out of 24 (38%) patients with initially KRAS WT tumours developed detectable mutations in KRAS between 5 and 6 months after the initiation of panitumumab monotherapy34. The gene discussed is KRAS; the disease is neoplasm.